DrugPatentWatch Database Preview
Investigational Drug Information for Ibudilast
Email this page to a colleague
What is the development status for investigational drug Ibudilast?
Ibudilast is an investigational drug.
There have been 19 clinical trials for Ibudilast.
The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2020.
The most common disease conditions in clinical trials are Sclerosis, Alcohol Drinking, and Motor Neuron Disease. The leading clinical trial sponsors are MediciNova, University of California, Los Angeles, and National Institute on Drug Abuse (NIDA).
There are eight hundred and seven US patents protecting this investigational drug and seven international patents.
Summary for Ibudilast
| US Patents | 807 |
| International Patents | 7,790 |
| US Patent Applications | 3,543 |
| WIPO Patent Applications | 1,345 |
| Japanese Patent Applications | 1,249 |
| Clinical Trial Progress | Phase 2 (2020-12-01) |
| Vendors | 93 |
Recent Clinical Trials for Ibudilast
| Title | Sponsor | Phase |
|---|---|---|
| Efficacy, Safety, Tolerability, and Biomarkers of MN-166 (Ibudilast) in Patients Hospitalized With COVID-19 and at Risk for ARDS | MediciNova | Phase 2 |
| Regeneration in Cervical Degenerative Myelopathy | Cambridge University Hospitals NHS Foundation Trust | Phase 3 |
| Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS | MediciNova | Phase 2/Phase 3 |
Clinical Trial Summary for Ibudilast
Top disease conditions for Ibudilast
Top clinical trial sponsors for Ibudilast
US Patents for Ibudilast
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Ibudilast | ⤷ Try it Free | Heterocyclic compound | Takeda Pharmaceutical Company Limited (Osaka, JP) | ⤷ Try it Free |
| Ibudilast | ⤷ Try it Free | Therapeutic approaches for treating Parkinson's disease | Pharnext (Issy les Moulineaux, FR) | ⤷ Try it Free |
| Ibudilast | ⤷ Try it Free | Tolerogenic synthetic nanocarriers for generating CD8+ regulatory T cells | Selecta Biosciences, Inc. (Watertown, MA) | ⤷ Try it Free |
| Ibudilast | ⤷ Try it Free | Method of purifying authentic trimeric HIV-1 GP140 envelope glycoproteins comprising a long linker and tag | The Catholic University of America (Washington, DC) | ⤷ Try it Free |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Ibudilast
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Ibudilast | Canada | CA2961033 | 2034-09-11 | ⤷ Try it Free |
| Ibudilast | European Patent Office | EP3192791 | 2034-09-11 | ⤷ Try it Free |
| Ibudilast | Japan | JPWO2016039408 | 2034-09-11 | ⤷ Try it Free |
| Ibudilast | World Intellectual Property Organization (WIPO) | WO2016039408 | 2034-09-11 | ⤷ Try it Free |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
